---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040980"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:09:18.880337+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Candel Q2 net loss $9.6M; CAN-2409 NSCLC Fast Track; cash runway through Q2 2024

## Summary
- Net loss of $9.6M in Q2 2023 vs $4.1M in Q2 2022, driven by higher R&D costs and warrant liability change.
- Cash and equivalents $51.9M as of June 30, 2023; expected to fund operations into Q2 2024.
- CAN-2409 granted FDA Fast Track Designation for NSCLC; topline overall survival data expected Q2 2024.
- CAN-3110 phase 1 recurrent HGG trial showed median OS of 11.8 months; repeat dosing arm enrolling.
- Initial overall survival data for CAN-2409 in borderline resectable pancreatic cancer expected Q4 2023.

## SEC filing metadata
- accession: 0000950170-23-040980
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023040980/0000950170-23-040980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023040980/cadl-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040980
- JSON: https://secwatch.observer/filing/0000950170-23-040980.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040980.txt

## Key facts
- Earnings Releases
  Candel Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $9.6 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss for the second quarter of 2023 was $9.6 million
  - Result: reported results
  source text: On August 10, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2023. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017023040980/0000950170-23-040980-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.